Home Cart Sign in  
Chemical Structure| 1835667-12-3 Chemical Structure| 1835667-12-3

Structure of Rezivertinib
CAS No.: 1835667-12-3

Chemical Structure| 1835667-12-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rezivertinib (BPI-7711) is a third-generation EGFR tyrosine kinase inhibitor effective against EGFR-sensitive mutations and T790M-resistant mutations. It possesses antitumor activity and can penetrate the central nervous system.

Synonyms: BPI-7711

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rezivertinib

CAS No. :1835667-12-3
Formula : C27H30N6O3
M.W : 486.57
SMILES Code : C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1OCCN(C)C)=O
Synonyms :
BPI-7711

Safety of Rezivertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Rezivertinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04135820 NSCLC PHASE1 COMPLETED 2020-03-25 Shanghai Ninth People's Hospit... More >>al, Shanghai, 200025, China Less <<
NCT03812809 NSCLC PHASE2 COMPLETED 2022-01-24 Cancer Hospital Chinese Academ... More >>y of Medical Sciences, Beijing, Beijing, 100021, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Linyi Cancer Hospital, Linyi, Shandong, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.28mL

2.06mL

1.03mL

20.55mL

4.11mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories